Toronto Dominion Bank Grows Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Toronto Dominion Bank boosted its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 11.0% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 710,523 shares of the biopharmaceutical company's stock after purchasing an additional 70,551 shares during the period. Toronto Dominion Bank owned about 0.06% of Gilead Sciences worth $65,631,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also recently made changes to their positions in the company. Norges Bank acquired a new position in shares of Gilead Sciences in the fourth quarter worth about $1,789,254,000. FMR LLC raised its holdings in Gilead Sciences by 21.6% in the 4th quarter. FMR LLC now owns 40,319,432 shares of the biopharmaceutical company's stock valued at $3,724,306,000 after acquiring an additional 7,157,113 shares during the last quarter. Pacer Advisors Inc. raised its holdings in Gilead Sciences by 723.3% in the 4th quarter. Pacer Advisors Inc. now owns 6,434,665 shares of the biopharmaceutical company's stock valued at $594,370,000 after acquiring an additional 5,653,075 shares during the last quarter. Northern Trust Corp raised its holdings in Gilead Sciences by 19.7% in the 4th quarter. Northern Trust Corp now owns 14,915,095 shares of the biopharmaceutical company's stock valued at $1,377,707,000 after acquiring an additional 2,458,954 shares during the last quarter. Finally, Raymond James Financial Inc. acquired a new stake in Gilead Sciences in the 4th quarter valued at about $207,340,000. 83.67% of the stock is owned by hedge funds and other institutional investors.

Gilead Sciences Stock Performance

Shares of NASDAQ:GILD traded up $2.95 on Tuesday, reaching $109.11. The company's stock had a trading volume of 10,711,437 shares, compared to its average volume of 7,704,931. The stock's 50-day moving average is $105.51 and its two-hundred day moving average is $100.02. The stock has a market capitalization of $135.73 billion, a P/E ratio of 294.89, a PEG ratio of 0.71 and a beta of 0.26. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.50 and a quick ratio of 1.20. Gilead Sciences, Inc. has a 52-week low of $62.07 and a 52-week high of $119.96.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.77 by $0.04. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. The firm had revenue of $6.67 billion during the quarter, compared to analysts' expectations of $6.77 billion. During the same quarter in the prior year, the business posted ($1.32) earnings per share. Gilead Sciences's revenue was down .3% compared to the same quarter last year. As a group, sell-side analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, June 27th. Stockholders of record on Friday, June 13th will be given a dividend of $0.79 per share. The ex-dividend date of this dividend is Friday, June 13th. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.90%. Gilead Sciences's payout ratio is 66.53%.

Wall Street Analyst Weigh In

A number of analysts have commented on GILD shares. Morgan Stanley increased their price objective on shares of Gilead Sciences from $130.00 to $135.00 and gave the company an "overweight" rating in a report on Friday, April 25th. Wells Fargo & Company boosted their price objective on shares of Gilead Sciences from $120.00 to $140.00 and gave the company an "overweight" rating in a report on Wednesday, March 5th. Needham & Company LLC reiterated a "hold" rating on shares of Gilead Sciences in a report on Friday, April 25th. Royal Bank of Canada lifted their target price on shares of Gilead Sciences from $84.00 to $90.00 and gave the company a "sector perform" rating in a report on Wednesday, February 12th. Finally, Cantor Fitzgerald started coverage on shares of Gilead Sciences in a report on Tuesday, April 22nd. They issued an "overweight" rating and a $125.00 target price for the company. Nine research analysts have rated the stock with a hold rating, fifteen have given a buy rating and three have issued a strong buy rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $110.55.

Insider Activity

In related news, CFO Andrew D. Dickinson sold 2,500 shares of Gilead Sciences stock in a transaction that occurred on Tuesday, April 15th. The stock was sold at an average price of $106.40, for a total transaction of $266,000.00. Following the completion of the transaction, the chief financial officer now directly owns 168,174 shares in the company, valued at $17,893,713.60. The trade was a 1.46% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. In the last three months, insiders sold 22,929 shares of company stock worth $2,634,220. Company insiders own 0.27% of the company's stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.